RHY.AX stock +26.67% to A$0.19 on 04 Feb 2026 ASX close: volume-led gain

RHY.AX stock jumped 26.67% to A$0.19 at the ASX close on 04 Feb 2026, driven by heavy trading and momentum into small-cap healthcare names. Volume reached 2,755,061 shares, about 4.27x the average, suggesting short-term buying pressure. The move made Rhythm Biosciences Limited (RHY.AX) a top gainer on the ASX market closed session. We examine the trade drivers, fundamentals, technicals and model forecasts to frame the risk-reward for investors.

Market move and immediate drivers for RHY.AX stock

RHY.AX stock closed at A$0.19, up A$0.04 from the prior close of A$0.15. Volume was 2,755,061 shares versus an average of 645,796, indicating a relVolume of 4.27. The session high was A$0.20 and the low was A$0.17.

The spike appears tied to momentum flows in small-cap healthcare stocks and renewed interest in Rhythm’s ColoSTAT tests. No formal broker upgrade was published. For context, the ASX Healthcare sector has lagged year-to-date, making isolated gains like this common in low-float names.

RHY.AX stock fundamentals and financial snapshot

Rhythm Biosciences (RHY.AX) has a market cap of A$62.14M and 327,068,419 shares outstanding. Reported EPS is -A$0.01 and the trailing PE reads -19.00, reflecting negative profitability. Price averages show recent improvement with a 50-day MA of A$0.12 and 200-day MA of A$0.09.

Key ratios highlight valuation risk. Price-to-sales is 19.47, price-to-book is 81.29, and current ratio is 0.84. Debt-to-equity is 1.68, and cash per share is A$0.01. These metrics show a cash-constrained, early commercial-stage company with high valuation multiples versus revenue.

Technicals, momentum and trading context for RHY.AX stock

Technical indicators show rising short-term momentum. RSI is 55.10, ADX is 36.75 indicating a strong trend, and MFI is 73.82, a sign of heavy buying. On-balance volume sits at 6,920,252, confirming net inflows.

Price sits above the 50-day and 200-day moving averages, which supports continued short-term momentum. Day range tightness and ATR of A$0.01 suggest higher volatility but clear intraday movement.

Meyka AI grade, forecast model and implied changes

Meyka AI rates RHY.AX with a score out of 100: 59.01 / 100 — Grade C+ — Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Grades are informational and not financial advice.

Meyka AI’s forecast model projects a monthly price of A$0.15, a quarterly price of A$0.10, and a yearly price of A$0.07239. Compared with the current A$0.19, the model implies a -21.05% change to the monthly figure, -47.37% to the quarterly figure, and -61.90% to the yearly figure. Forecasts are model-based projections and not guarantees.

Valuation, analyst signals and upcoming catalysts for RHY.AX stock

Independent company rating data shows a recent score of C- with a recommendation of Strong Sell dated 03 Feb 2026. There is no published price target consensus. Rhythm lists an earnings announcement on 20 Feb 2026, which could be a near-term catalyst for updated guidance or cash disclosures.

Watch commercial milestones for ColoSTAT, regulatory news, and cash runway details. Small-cap healthcare names often move on partnership or trial updates. Given current valuation multiples, material progress in revenue or approvals is likely required to justify higher levels.

Risks and opportunities in RHY.AX stock

Opportunity: Rhythm’s ColoSTAT blood test addresses colorectal cancer screening. Commercial adoption or favourable trial results could rapidly increase revenue potential and re-rate the stock.

Risk: The company shows negative earnings and tight liquidity. High price-to-book and price-to-sales ratios mean share price moves reflect sentiment more than fundamentals. Trading liquidity can amplify volatility; investors should size positions accordingly.

Final Thoughts

RHY.AX stock was a top gainer on the ASX close on 04 Feb 2026, rising 26.67% to A$0.19 on heavy volume. The move reflects momentum and renewed interest in Rhythm Biosciences’ ColoSTAT story. Fundamentals show negative EPS (-A$0.01), high valuation multiples like P/S 19.47 and P/B 81.29, and a current ratio below 1, signalling financial risk. Meyka AI’s model projects a yearly price of A$0.07239, an implied -61.90% from today. For traders, short-term momentum and technicals support follow-through above A$0.20. For longer-term investors, progress on commercial adoption, upcoming earnings on 20 Feb 2026, and cash runway are the key catalysts to watch. We suggest monitoring volume, regulatory updates, and any partnership announcements. Meyka AI provides this AI-powered market analysis as informational insight; forecasts are model outputs, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.